Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR.

JCI Insight. 2019 Oct 3;4(19). pii: 127716. doi: 10.1172/jci.insight.127716.

2.

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GvHD.

Koehn BH, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L, Zaiken M, Dysthe J, Krepps W, Panthera J, Hippen K, Jameson SC, Miller JS, Cooper MA, Farady CJ, Iwawaki T, Ting JP, Serody JS, Murphy WJ, Hill GR, Murray PJ, Bronte V, Munn DH, Zeiser R, Blazar BR.

Blood. 2019 Sep 18. pii: blood.2019001950. doi: 10.1182/blood.2019001950. [Epub ahead of print]

PMID:
31533918
3.

Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.

Nat Commun. 2019 Aug 15;10(1):3680. doi: 10.1038/s41467-019-11563-5.

4.

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.

Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1. Erratum in: Nat Commun. 2019 Aug 15;10(1):3680.

5.

Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.

Thangavelu G, Lee YC, Loschi M, Schaechter KM, Feser CJ, Koehn BH, Nowak EC, Zeiser R, Serody JS, Murphy WJ, Munn DH, Chambon P, Noelle RJ, Blazar BR.

J Immunol. 2019 May 1;202(9):2795-2805. doi: 10.4049/jimmunol.1800899. Epub 2019 Mar 18.

PMID:
30885956
6.

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Jun;19(6):1820-1830. doi: 10.1111/ajt.15305. Epub 2019 Mar 19.

PMID:
30748099
7.

Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.

Munn DH, Sharma MD, Johnson TS.

Cancer Res. 2018 Sep 15;78(18):5191-5199. doi: 10.1158/0008-5472.CAN-18-1351. Epub 2018 Sep 4. Review.

8.

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.

McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, Kirchmeier AK, Osborn MJ, Hippen KL, Kelekar A, Serody JS, Turka LA, Munn DH, Chi H, Neubert TA, Dustin ML, Blazar BR.

J Clin Invest. 2018 Oct 1;128(10):4604-4621. doi: 10.1172/JCI95713. Epub 2018 Aug 14.

9.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN.

J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9.

10.

Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Habtetsion T, Ding ZC, Pi W, Li T, Lu C, Chen T, Xi C, Spartz H, Liu K, Hao Z, Mivechi N, Huo Y, Blazar BR, Munn DH, Zhou G.

Cell Metab. 2018 Aug 7;28(2):228-242.e6. doi: 10.1016/j.cmet.2018.05.012. Epub 2018 Jun 7.

11.

Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans.

Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, Deol R, Manion KP, Baglaenko Y, Eldh M, Lamorte S, Wallace D, Chodisetti SB, Ravishankar B, Liu H, Chaudhary K, Munn DH, Tsirigos A, Madaio M, Gabrielsson S, Touma Z, Wither J, De Carvalho DD, McGaha TL.

Nat Immunol. 2018 Jun;19(6):571-582. doi: 10.1038/s41590-018-0107-1. Epub 2018 May 14.

12.

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors.

Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, Bronte V, Wolchok JD, Blazar BR, Munn DH.

Immunity. 2018 Jan 16;48(1):91-106.e6. doi: 10.1016/j.immuni.2017.12.014.

13.

The host protecting the tumor from the host - targeting PD‑L1 expressed by host cells.

Munn DH.

J Clin Invest. 2018 Feb 1;128(2):570-572. doi: 10.1172/JCI99047. Epub 2018 Jan 16.

14.

Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Johnson TS, Mcgaha T, Munn DH.

Adv Exp Med Biol. 2017;1036:91-104. doi: 10.1007/978-3-319-67577-0_7. Review.

15.

Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells.

Ding ZC, Habtetsion T, Cao Y, Li T, Liu C, Kuczma M, Chen T, Hao Z, Bryan L, Munn DH, Zhou G.

Sci Rep. 2017 Sep 22;7(1):12168. doi: 10.1038/s41598-017-12488-z.

16.

IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.

Munn DH, Sharma MD, Johnson TS, Rodriguez P.

Cancer Immunol Immunother. 2017 Aug;66(8):1049-1058. doi: 10.1007/s00262-017-2010-2. Epub 2017 May 9. Review.

17.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

18.

Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.

Noonepalle SK, Gu F, Lee EJ, Choi JH, Han Q, Kim J, Ouzounova M, Shull AY, Pei L, Hsu PY, Kolhe R, Shi F, Choi J, Chiou K, Huang TH, Korkaya H, Deng L, Xin HB, Huang S, Thangaraju M, Sreekumar A, Ambs S, Tang SC, Munn DH, Shi H.

Cancer Immunol Res. 2017 Apr;5(4):330-344. doi: 10.1158/2326-6066.CIR-16-0182. Epub 2017 Mar 6.

19.

miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar BR.

Blood. 2016 Sep 8;128(10):1424-35. doi: 10.1182/blood-2016-05-714535. Epub 2016 Aug 2.

20.

IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

Ding ZC, Liu C, Cao Y, Habtetsion T, Kuczma M, Pi W, Kong H, Cacan E, Greer SF, Cui Y, Blazar BR, Munn DH, Zhou G.

Oncoimmunology. 2016 Apr 25;5(6):e1171445. doi: 10.1080/2162402X.2016.1171445. eCollection 2016 Jun.

21.

Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.

McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KP, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, Munn DH, Turka LA, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Blazar BR.

Blood. 2016 Aug 18;128(7):1013-7. doi: 10.1182/blood-2016-05-715896. Epub 2016 Jul 6.

22.

An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis.

Sivaprakasam S, Gurav A, Paschall AV, Coe GL, Chaudhary K, Cai Y, Kolhe R, Martin P, Browning D, Huang L, Shi H, Sifuentes H, Vijay-Kumar M, Thompson SA, Munn DH, Mellor A, McGaha TL, Shiao P, Cutler CW, Liu K, Ganapathy V, Li H, Singh N.

Oncogenesis. 2016 Jun 27;5(6):e238. doi: 10.1038/oncsis.2016.38.

23.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR.

J Clin Invest. 2016 Jul 1;126(7):2642-60. doi: 10.1172/JCI85796. Epub 2016 Jun 13.

24.

Virus Infections Incite Pain Hypersensitivity by Inducing Indoleamine 2,3 Dioxygenase.

Huang L, Ou R, Rabelo de Souza G, Cunha TM, Lemos H, Mohamed E, Li L, Pacholczyk G, Randall J, Munn DH, Mellor AL.

PLoS Pathog. 2016 May 11;12(5):e1005615. doi: 10.1371/journal.ppat.1005615. eCollection 2016 May.

25.

Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity.

Hong Y, Manoharan I, Suryawanshi A, Shanmugam A, Swafford D, Ahmad S, Chinnadurai R, Manicassamy B, He Y, Mellor AL, Thangaraju M, Munn DH, Manicassamy S.

Oncoimmunology. 2015 Dec 14;5(4):e1115941. eCollection 2016 Apr.

26.

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Munn DH, Mellor AL.

Trends Immunol. 2016 Mar;37(3):193-207. doi: 10.1016/j.it.2016.01.002. Epub 2016 Jan 31. Review.

27.

Immune suppressive mechanisms in the tumor microenvironment.

Munn DH, Bronte V.

Curr Opin Immunol. 2016 Apr;39:1-6. doi: 10.1016/j.coi.2015.10.009. Epub 2015 Nov 21. Review.

28.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

29.

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD.

Cell Rep. 2015 Oct 13;13(2):412-24. doi: 10.1016/j.celrep.2015.08.077. Epub 2015 Sep 24.

30.

GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR.

Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.

31.

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality.

Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknecht E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR.

Blood. 2015 May 21;125(21):3335-46. doi: 10.1182/blood-2014-09-603357. Epub 2015 Mar 26. Erratum in: Blood. 2016 Jun 16;127(24):3104.

32.

Canonical wnt signaling in dendritic cells regulates Th1/Th17 responses and suppresses autoimmune neuroinflammation.

Suryawanshi A, Manoharan I, Hong Y, Swafford D, Majumdar T, Taketo MM, Manicassamy B, Koni PA, Thangaraju M, Sun Z, Mellor AL, Munn DH, Manicassamy S.

J Immunol. 2015 Apr 1;194(7):3295-304. doi: 10.4049/jimmunol.1402691. Epub 2015 Feb 20.

33.
34.

β-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells.

Hong Y, Manoharan I, Suryawanshi A, Majumdar T, Angus-Hill ML, Koni PA, Manicassamy B, Mellor AL, Munn DH, Manicassamy S.

Cancer Res. 2015 Feb 15;75(4):656-665. doi: 10.1158/0008-5472.CAN-14-2377. Epub 2015 Jan 7.

35.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR.

J Clin Invest. 2014 Nov;124(11):4867-76. doi: 10.1172/JCI75328. Epub 2014 Oct 1.

36.

TLR2-dependent activation of β-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammation.

Manoharan I, Hong Y, Suryawanshi A, Angus-Hill ML, Sun Z, Mellor AL, Munn DH, Manicassamy S.

J Immunol. 2014 Oct 15;193(8):4203-13. doi: 10.4049/jimmunol.1400614. Epub 2014 Sep 10.

37.

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, Hoang K, Ashley C, McCall D, Rojiani AM, Maria BL, Rixe O, MacDonald TJ, Heeger PS, Mellor AL, Munn DH, Johnson TS.

J Immunother Cancer. 2014 Jul 7;2:21. doi: 10.1186/2051-1426-2-21. eCollection 2014.

38.

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, MacDonald KP, Hill GR, Blazar BR.

Blood. 2014 Jun 19;123(25):3988-98. doi: 10.1182/blood-2014-03-562231. Epub 2014 May 12.

39.

Activation of the STING adaptor attenuates experimental autoimmune encephalitis.

Lemos H, Huang L, Chandler PR, Mohamed E, Souza GR, Li L, Pacholczyk G, Barber GN, Hayakawa Y, Munn DH, Mellor AL.

J Immunol. 2014 Jun 15;192(12):5571-8. doi: 10.4049/jimmunol.1303258. Epub 2014 May 5.

40.

Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.

Ding ZC, Lu X, Yu M, Lemos H, Huang L, Chandler P, Liu K, Walters M, Krasinski A, Mack M, Blazar BR, Mellor AL, Munn DH, Zhou G.

Cancer Res. 2014 Jul 1;74(13):3441-53. doi: 10.1158/0008-5472.CAN-13-3596. Epub 2014 Apr 29.

41.

Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance.

Ravishankar B, Shinde R, Liu H, Chaudhary K, Bradley J, Lemos HP, Chandler P, Tanaka M, Munn DH, Mellor AL, McGaha TL.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4215-20. doi: 10.1073/pnas.1320924111. Epub 2014 Mar 3.

42.

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H.

Cancer Immunol Res. 2013 Aug;1(2):123-33. doi: 10.1158/2326-6066.CIR-13-0058.

43.

Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis.

Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, Thangaraju M, Prasad PD, Manicassamy S, Munn DH, Lee JR, Offermanns S, Ganapathy V.

Immunity. 2014 Jan 16;40(1):128-39. doi: 10.1016/j.immuni.2013.12.007. Epub 2014 Jan 9.

44.

GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology.

Liu H, Huang L, Bradley J, Liu K, Bardhan K, Ron D, Mellor AL, Munn DH, McGaha TL.

Mol Cell Biol. 2014 Feb;34(3):428-38. doi: 10.1128/MCB.00946-13. Epub 2013 Nov 18.

45.

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Hong Y, Peng Y, Guo ZS, Guevara-Patino J, Pang J, Butterfield LH, Mivechi NF, Munn DH, Bartlett DL, He Y.

Hepatology. 2014 Apr;59(4):1448-58. doi: 10.1002/hep.26893. Epub 2014 Feb 18.

46.

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, Munn DH, Murphy WJ, Azuma M, Yagita H, Fife BT, Sayegh MH, Najafian N, Socie G, Ahmed R, Freeman GJ, Sharpe AH, Blazar BR.

Blood. 2013 Oct 24;122(17):3062-73. doi: 10.1182/blood-2013-05-500801. Epub 2013 Sep 12.

47.

Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses.

Huang L, Li L, Lemos H, Chandler PR, Pacholczyk G, Baban B, Barber GN, Hayakawa Y, McGaha TL, Ravishankar B, Munn DH, Mellor AL.

J Immunol. 2013 Oct 1;191(7):3509-13. doi: 10.4049/jimmunol.1301419. Epub 2013 Aug 28.

48.

Indoleamine 2,3-dioxygenase 1 (ido1) is involved in the control of mouse caput epididymis immune environment.

Jrad-Lamine A, Henry-Berger J, Damon-Soubeyrand C, Saez F, Kocer A, Janny L, Pons-Rejraji H, Munn DH, Mellor AL, Gharbi N, Cadet R, Guiton R, Aitken RJ, Drevet JR.

PLoS One. 2013 Jun 20;8(6):e66494. doi: 10.1371/journal.pone.0066494. Print 2013.

49.

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.

Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.

Blood. 2013 Sep 19;122(12):2125-34. doi: 10.1182/blood-2012-11-470252. Epub 2013 Jun 27.

50.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10.

Supplemental Content

Support Center